Last $189.53 USD
Change Today +0.57 / 0.30%
Volume 2.1M
ALXN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Scott Rollins Ph.D.

AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

51--

Background*

Dr. Scott A. Rollins, Ph.D. is a Co-Founder of Selexys Pharmaceuticals Corporation and has been its Chief Executive Officer and President since March 1, 2008. Dr. Rollins Co-founded Alexion Pharmaceuticals Inc. in 1992 and served as its Senior Vice President for Drug Development and Project Management since September 2002. Dr. Rollins was responsible for the pre-clinical development of Alexion Pharmaceuticals Inc. anti-inflammatory compound pexelizumab since 1994. Dr. ...

Read Full Background

Corporate Headquarters*

352 Knotter Drive
Cheshire, Connecticut 06410

United States

Phone: 203-272-2596
Fax: 203-271-8198

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

PhD
University of Oklahoma Health Sciences Center
BS
University of Oklahoma Health Sciences Center

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $189.53 USD +0.57

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.